Pack de 10 flacons4 en stockÉconomisez 25 %Retatrutide 10 mg
Peptide de recherche tri-agoniste GLP-1 / GIP / glucagon
Retatrutide tri-agonist research peptide, Australian-shipped. Lab-verified ≥99% purity.
Usage exclusivement réservé à la recherche. Ce composé est vendu strictement pour la recherche in vitro et à des fins de laboratoire, et n’est pas destiné à la consommation humaine ni à un usage thérapeutique. En achetant, vous confirmez être un chercheur qualifié et acceptez notre avertissement complet.
Plus que 4 packs
Peptide de recherche agoniste de triple récepteur, étudié pour ses effets combinés sur les voies de signalisation GLP-1, GIP et glucagon en recherche métabolique.
Retatrutide is a synthetic tri-agonist research peptide that activates the GLP-1, GIP, and glucagon receptors simultaneously. It is part of a new generation of incretin-receptor research compounds developed to study combined activation of multiple metabolic pathways. Quantum Labs supplies Retatrutide as a lyophilised powder for Australian research applications.
Retatrutide is studied alongside other incretin-receptor agonists — semaglutide (single-agonist GLP-1) and tirzepatide (dual-agonist GLP-1/GIP) — in pre-clinical and clinical research literature. The tri-agonist mechanism is the distinguishing feature that places it in its own research category. Material is HPLC-verified to ≥99% purity and ships from Australian stock; supplied for laboratory research use only.
Mécanisme
Étudié pour l’agonisme simultané des récepteurs GLP-1, GIP et glucagon. Recherche associée aux marqueurs de taux métabolique, de satiété et de dépense énergétique.
Vérifié par HPLC selon une spécification de pureté ≥99 %. Analysé de manière indépendante par des laboratoires tiers accrédités.
Retatrutide — questions fréquentes
What is Retatrutide?
Retatrutide is a synthetic tri-agonist research peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. It is a newer-generation incretin-receptor research compound.
Is Retatrutide legal in Australia?
Retatrutide is not an approved therapeutic in Australia and remains available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies Retatrutide for research use only — it is not a substitute for prescription weight-loss medication.
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual-agonist activating GLP-1 and GIP receptors. Retatrutide is a tri-agonist activating GLP-1, GIP, and glucagon receptors. The added glucagon-receptor activity is the distinguishing pharmacological feature of Retatrutide.
What is the difference between Retatrutide and Mounjaro?
Mounjaro is the brand name for the approved prescription medicine tirzepatide. Retatrutide is a separate research peptide with an additional glucagon-receptor agonism. They are different molecules studied in parallel research literature. Quantum Labs does not supply prescription medicines.
What is the typical Retatrutide research dosage?
Published clinical research has used Retatrutide doses across a wide titration range. Research-protocol dosing varies by model. Human therapeutic dosing is not established. Quantum Labs supplies this compound for laboratory and pre-clinical research use only. It is not represented for human therapeutic use, and questions about clinical dosing, treatment effects, or personal use should be directed to a qualified medical practitioner.
Guides liés à Retatrutide
Les chercheurs explorent aussi
Pack de 10 flaconsÉconomisez 22 %MOTS-c
Poudre lyophilisée10 mg · 2 strengths
Peptide métabolique d’origine mitochondriale
Dans 2 combinaisons
Pack de 10 flaconsÉconomisez 16 %5-Amino-1MQ
Poudre lyophilisée50 mg · 3 strengths
Composé de recherche inhibiteur de NNMT
Pack de 10 flaconsÉconomisez 15 %L-Carnitine
Sterile solution10 ml × 600 mg/ml
Transporteur mitochondrial d’acides gras
Dans 1 combinaison